EPIDEMIOLOGY OF INSULIN PUMP THERAPY IN ITALY: THE IMITAS STUDIES in 9th International Conference on Advanced Technologies & Treatment of Diabetes (ATTD) Barcellona 2016

Background: continuous subcutaneous insulin infusion (CSII) is increasing due to effectiveness and improved technology. Aim: to evaluate the current status of CSII in Italy. Materials and Methods: clinical features, pump technology, patient management and metabolic control of CSII patients were investigated in two questionnaire-based surveys to 272 Italian diabetes centers. Results: 217 centers (79,8%) answered the first questionnaire giving information on 10,152 patients, 98.2% with type 1 diabetes mellitus, 81,4% adults, 57% female, 61% with a conventional pump and 39% with a sensoraugmented pump. CSII advanced functions were used by 68% of patients, and glucose sensors were used 12 days/month on average. Fifty-eight percent of centers had >20 CSII patients. Main indication for CSII was poor glucose control. Dropout was mostly due to pump wearability or bad glucose control. A complete dedicated team was available in 23% of adult centers and in 53% of pediatric units. In the second survey, data were obtained from 114 centers on 6,886 patients with overall characteristics comparable to the previous one. Mean HbA1c was 60.1 ± 10.7 mM/M. Lower HbA1c levels were associated to age 6–13, pregnancy in the last year, use of advanced functions, sensor use ≥10 days/month, availability of a dedicated team. 6,1% of patients had ≥1 severe hypoglycemic event over the previous year. Conclusions: Advanced patient skills, compliance to sensor use and an integrated team approach are associated to better metabolic outcomes in Italian CSII patients.